BETA
Your AI-Trained Oncology Knowledge Connection!
Phase 2b Trial for Cancer Vaccine in Newly Diagnosed Glioblastoma Will Continue
An independent data safety monitoring board determines that the phase 2b SURVIVE trial in newly diagnosed glioblastoma may continue without modification.
FDA Grants THE001 Orphan Drug Designation for Soft Tissue Sarcomas
The FDA designation follows an orphan drug designation granted by the European Medicines Agency for THE001 in patients with soft tissue sarcoma.
Advancing the Glioma Treatment Paradigm With Immunotherapy and Novel Strategies
Nicholas Blondin, MD, provides an in-depth discussion on the evolving role of immunotherapy in the treatment of primary and metastatic brain tumors.
Highlighting Advancements in Personalized T-Cell Lymphoma Treatment
Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.
67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery
Lorlatinib Yields No Unexpected Toxicities in ALK-Positive NSCLC
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
TFOX Regimen Enhances Efficacy vs FOLFOX in HER2-Negative Gastric Cancer
The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.
A Strong Network of Clinicians Makes Cancer Care More Efficient
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
68 Upper Extremity Disability Assessment Following Breast Cancer Surgery Using QuickDASH in an Ethnic Minority Population
Lorlatinib Demonstrates “Fantastic” PFS Results in Advanced ALK+ NSCLC
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
Breastfeeding Support May Reduce TNBC Incidence, Mitigate Disparities
Policy changes supporting breastfeeding may address structural barriers and lower overall incidence and racial disparities surrounding TNBC in the US.
Fostering Multidisciplinary Care May Reduce Oncologist Workplace Burnout
Joseph C. Landolfi, DO, CPE, and Michele Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Fruquintinib Combo Shows Early Activity in RAS/BRAF+ Metastatic CRC
At the time of analysis, the median progression-free survival was not reached with fruquintinib plus capecitabine in a phase 1/2 trial.
70 Malignancy Upgrade Rates of Discordant Breast Lesions
Revumenib Yields Meaningful Benefit in NPM1-Mutated Acute Myeloid Leukemia
Phase 2 data support the potential of revumenib to advance the standard of care for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
Chemoradiation Shows Responses Across Dose Levels in Anal Cancer
Phase 2 data indicate that reduced-dose chemoradiotherapy may be tolerable among patients with early-stage anal cancer.
Durvalumab Combo Demonstrates DFS Improvement in High-Risk NMIBC
Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.
ProstACT GLOBAL Results May Support “Open” Decisions in Metastatic CRPC
Findings from prior studies, such as the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Communication Between Leadership and Clinicians Improves Cancer Care
Leaders of a new cancer center, which is part of JFK University Medical Center, discuss how they can support frontline clinicians.
Highlighting “Trickle-Down” Progress in Developing Rare Lymphoma Treatment
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
71 Beyond the Surface: Suspicious Nipple Lesions
Frontline Efti Combo Yields Meaningful Survival in PD-L1–Low HNSCC
Survival data with eftilagimod alfa plus pembrolizumab compare favorably with historical results seen with standard-of-care therapies in this population.
Frontline ICI Therapy Confers OS Benefit in MSI-H Metastatic CRC
Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.
FDA Grants Accelerated Approval to Avutometinib/Defactinib in KRAS+ LGSOC
Findings from the phase 2 RAMP 201 trial support the FDA approval of avutometinib plus defactinib in low-grade serous ovarian cancer.
Elraglusib Combo Demonstrates OS Benefit in Metastatic Pancreatic Cancer
The phase 2 Actuate 1801 part 3b trial results evaluating elraglusib with GnP in metastatic PDAC will be presented at the 2025 ASCO Annual Meeting.
Concurrent Chemoradiation May Improve LS-SCLC Prognosis
Whole-brain prophylactic cranial irradiation appears to confer minimal overall survival benefits in those with limited-stage small cell lung cancer.
Cemsidomide Combo May Produce Responses in Multiple Myeloma
Investigators of the phase 1/2 CFT7455-1101 study have determined cemsidomide at a dose of 100 µg safe for expansion.
Perseverance Underscores Success in Rare Lymphoma Research
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
72 Breast Cancer After Breast Augmentation: A Multicenter Collaborative Study Of Patient Management and Outcomes
FDA Gives Fast-Track Designation to ISB 2001 in Relapsed/Refractory Myeloma
Phase 1 data demonstrate enduring responses with ISB 2001 among patients with relapsed/refractory multiple myeloma.
!["Policy changes aimed at supporting and more broadly enabling breastfeeding, addressing structural barriers, and promoting a culture shift could reduce overall incidence and racial disparities in TNBC incidence in the [US]," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fc33b85fa4b3edf9bdd0a6d37d81eee57f71a7348-1200x960.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"Policy changes aimed at supporting and more broadly enabling breastfeeding, addressing structural barriers, and promoting a culture shift could reduce overall incidence and racial disparities in TNBC incidence in the [US],\" according to the study authors.")
!["[G]iven the improvements in compliance and tolerability of the de-escalated regimen in older patients, with preserved early cancer outcomes, this reduced-dose regimen could be considered a new treatment option for [patients who are] frailer [and] not fit for standard-dose chemoradiotherapy," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F8987adec8367653dbaf8fc0f82c7dbfcb914281e-500x404.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[G]iven the improvements in compliance and tolerability of the de-escalated regimen in older patients, with preserved early cancer outcomes, this reduced-dose regimen could be considered a new treatment option for [patients who are] frailer [and] not fit for standard-dose chemoradiotherapy,\" according to the study authors.")
!["Early [concurrent] CRT provides a significant survival benefit, while late [concurrent] CRT is an acceptable option," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Ffc2a0cb8c6d287fa539f7d61aad18a8752d347dc-1200x882.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"Early [concurrent] CRT provides a significant survival benefit, while late [concurrent] CRT is an acceptable option,\" according to the study authors.")
